Biology of Blood and Marrow Transplantation
Volume 17, Issue 5 , Pages 703-709 , May 2011

Evaluating the Impact of Antithymocyte Globulin on Lung Function at 1 Year after Allogeneic Stem Cell Transplantation

  • Filippo Milano

      Affiliations

    • Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
    • Department of Cellular Biotechnologies and Haematology, University “La Sapienza,” Rome, Italy
    • Corresponding Author InformationCorrespondence and reprint requests: Filippo Milano, 1100 Fairview Avenue North, Mailstop D2-100, Seattle, WA 98109-1024.
    • ,
  • Margaret A. Au

      Affiliations

    • Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, Washington
    • Department of Epidemiology, Cancer Research Center, University of Hawaii, Honolulu, Hawaii
    • ,
  • Michael J. Boeckh

      Affiliations

    • Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
    • Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, Washington
    • ,
  • H. Joachim Deeg

      Affiliations

    • Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
    • Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, Washington
    • ,
  • Jason W. Chien

      Affiliations

    • Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
    • Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, Washington

Received 30 June 2010 ,Accepted 14 August 2010.

References 

  1. Breuer R, Lossos IS, Berkman N, et al. Pulmonary complications of bone marrow transplantation. Respir Med. 1993;87:571–579
  2. Cordonnier B, Bierling JF, Vernant JP, et al. Pulmonary complications occurring after allogeneic bone marrow transplantation: a study of 130 consecutive transplanted patients. Cancer. 1986;58:1047–1054
  3. Beinert T, Dull T, Kolb H, et al. Late pulmonary impairment following allogeneic bone marrow transplantation. Eur J Med Res. 1996;1:343–348
  4. Soubani AO, Miller KB, Hassoun PM. Pulmonary complications of bone marrow transplantation. Chest. 1996;109:1066–1077
  5. Patriarca F, Sperotto A, Fanin R, et al. Incidence, outcome, and risk factors of late-onset noninfectious pulmonary complications after unrelated donor stem cell transplantation. Bone Marrow Transplant. 2004;33:751–758
  6. Yoshihara S, Yanik G, Cooke KR, et al. Bronchiolitis obliterans syndrome (BOS), bronchiolitis obliterans organizing pneumonia (BOOP), and other late-onset noninfectious pulmonary complications following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13:749–759
  7. Chien JW, Martin PJ, Gooley TA, et al. Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. Am J Respir Crit Care Med. 2003;168:208–214
  8. Chien JW, Maris MB, Clark JG, et al. Comparison of lung function after myeloablative and 2 Gy of total body irradiation–based regimens for hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11:288–296
  9. Santo Tomas LH, Loberiza FR, Horowitz MM, et al. Risk factors for bronchiolitis obliterans in allogeneic hematopoietic stem cell transplantation for leukemia. Chest. 2005;128:153–161
  10. Sakaida E, Nakaseko C, Nishimura M, et al. Late-onset noninfectious pulmonary complications after allogeneic stem cell transplantation are significantly associated with chronic graft-versus-host disease and with the graft-versus-leukemia effect. Blood. 2003;102:4236–4242
  11. Ditschkowski M, Elmaagacli AH, Beelen DW, et al. T-cell depletion prevents from bronchiolitis obliterans and bronchiolitis obliterans with organizing pneumonia after allogeneic hematopoietic stem cell transplantation with related donors. Haematologica. 2007;92:558–561
  12. Yoshihara S, Tateishi U, Mineishi S, et al. Lower incidence of bronchiolitis obliterans in allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning compared with myeloablative conditioning. Bone Marrow Transplant. 2005;35:1195–1200
  13. Freudenberger TD, Madtes DK, Hackman RC, et al. Association between acute and chronic graft versus host disease and bronchiolitis obliterans organizing pneumonia in recipients of hematopoietic stem cell transplanst. Blood. 2003;102:3822–3828
  14. Deeg HJ, Storer BE, Boeckh M, et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant. 2006;12:573–584
  15. Bacigalupo A. Antithymocyte globulin for prevention of graft-versus-host disease. Curr Opin Hematol. 2005;12:457–462
  16. Bacigalupo A, Bosi A, Bruzzi P, et al. Antithymocyte globulin (ATG) prevents severe acute graft versus host disease (GVHD) in unrelated donor transplants: two randomized studies from the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Bone Marrow Transplant. April 2001;27:Supplement 1, S170-S179
  17. Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: two randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 2001;98:2942–2947
  18. Bacigalupo A, Lamparelli T, Bosi A, et al. Thymoglobulin prevents chronic graft-versus-host-disease, chronic lung dysfunction, and late transplanted-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant. 2006;12:560–565
  19. Nichols WG, Erdman DD, Boeckh M, et al. Prolonged outbreak of human parainfluenza virus 3 infection in a stem cell transplant outpatient department: insights from molecular epidemiologic analysis. Biol Blood Marrow Transplant. 2004;10:58–64
  20. Mielcarek M, Storer BE, Boeckh M, et al. Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood. 2009;113:2888–2894
  21. Przepiorka D, Smith TL, Folloder J, et al. Risk factors for acute graft versus host disease after allogeneic blood stem cell transplantation. Blood. 1999;94:1465–1470
  22. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host-disease, I: Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2005;11:945–956
  23. American Thoracic Society . Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis. 1991;144:1202–1218
  24. Crapo R, Morris A, Gardner R. Reference spirometric values using techniques and equipment that meet ATS reccomendations. Am Rev Respir Dis. 1981;123:659–664
  25. Parimon T, Madtes DK, Chien JW, et al. Pretransplant lung function, respiratory failure, and mortality after stem cell transplantation. Am J Respir Crit Care Med. 2005;172:384–390
  26. Ramirez-Sarmiento A, Orozco-Levi M, Chien JW, et al. Influence of pretransplantation restrictive lung disease on allogeneic hematopoietic cell transplantation outcomes. Biol Blood Marrow Transplant. 2010;16:199–206
  27. Williams KM, Chien JW, Gladwin MT, et al. Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA. 2009;302:306–314
  28. Byrne JL, Stainer C, Cull G, et al. The effect of serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host-disease and outcome following unrelated donor bone marrow transplantation for leukemia. Bone Marrow Transplant. 2000;25:411–417
  29. Storb R, Etzioni R, Anasetti C, et al. Cyclophoshamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood. 1994;84:941–949
  30. Chien JW, Martin PJ, Clark AG, et al. Implications of early airflow decline after myeloablative allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2004;33:759–764
  31. Cooper JAD, White DA, Matthay RA. Drug-induced pulmonary disease, part 1: cytotoxic drugs. Am Rev Respir Dis. 1986;133:321–340
  32. Vergnon JM, Bouchero S, Emonot A, et al. Interstitial pneumopathies caused by busulfan: histologic developmental and bronchoalveolar lavage analysis of 3 cases. Rev Med Intern. 1998;9:377–383
  33. Burns WA, McFarland W, Matthews MJ. Busulfan-induced pulmonary disease: report of a case and review of the literature. Am Rev Respir Dis. 1970;101:408–413
  34. Barret A. Relationship of irradiation to pulmonary complications. Exp Hematol. 1984;12:6–7
  35. Weshler Z, Breuer R, Or R, et al. Interstitial pneumonitis after total body irradiation: effects of total lung shielding. Br J Haematol. 1990;74:61–64
  36. Schultz KR, Green GJ, Wensley JL, et al. Obstructive lung disease in children after allogeneic bone marrow transplantation. Blood. 1994;9:3212–3220
  37. Remberger M, Mattsson J, Ringden O. Polyclonal anti–T cell globulin as part of the preparative regimen for pediatric allogeneic stem-cell transplantation. Pediatr Transplant. 2001;5:285–292
  38. Russell JA, Tran HT, Quinlan D, et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant. 2002;8:468–476
  39. Erard V, Chien JW, Boeckh M, et al. Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: the role of community respiratory viruses. J Infect Dis. 193;12:1619–1625.

 Financial disclosure: See Acknowledgments on page 708.

PII: S1083-8791(10)00351-4

doi: 10.1016/j.bbmt.2010.08.012

Biology of Blood and Marrow Transplantation
Volume 17, Issue 5 , Pages 703-709 , May 2011

Article Tools

* Image Usage & Resolution